Keywords: Left ventricular mass (LVM); LVM regression; cardiovascular mortality; chronic kidney disease (CKD); left ventricular hypertrophy; surrogate endpoint; surrogate outcome; cardioprotection; erythropoiesis-stimulating agent (ESA); renin-angiotensin-aldostero
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Dialysis; epoetin alfa; recombinant human erythropoietin (rHuEPO); erythropoiesis-stimulating agent (ESA); dose; EPO titration; hemoglobin; red blood cell transfusion rate; anemia management; practice patterns; hospitalization; Medicare reimbursement; end
Keywords: Health-related quality of life (HRQoL); hemodialysis (HD); anemia; erythropoiesis-stimulating agent (ESA); intravenous iron; dosing pattern; bolus dosing; maintenance dosing; epoetin alfa; hemoglobin; transferrin saturation (TSAT); chronic kidney disease
Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018
Keywords: anemia; chronic kidney disease (CKD); erythropoietin deficiency; iron; hemoglobin; erythropoiesis; erythropoiesis-stimulating agent (ESA); epoetin alfa; darbepoeitin alfa; cardiovascular disease; quality of life; fatigue; review;
A Novel Hypoxia-Inducible FactorâProlyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
Keywords: Erythropoietin (EPO); hypoxia-inducible factor (HIF); prolyl hydroxylase inhibitor (PHI); hemoglobin response rate; pharmacokinetics; pharmacodynamics; dosing; erythropoiesis-stimulating agent (ESA); hemoglobin; reticulocyte count; hepcidin; chronic kidne
Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis
Keywords: Iron; anemia; IV iron; oral iron; iron supplementation; chronic kidney disease (CKD); dialysis; end-stage renal disease (ESRD); haemoglobin; Hb response; transferrin saturation (TSAT); ferritin; erythropoiesis-stimulating agent (ESA); blood transfusion; q
The Emerging Role of Biosimilar Epoetins in Nephrology in the United States
Keywords: Biologic; biosimilar; bioequivalent drug; epoetin; epoetin alfa; epoetin zeta; recombinant human erythropoietin (rHuEPO); erythropoiesis-stimulating agent (ESA); anemia; chronic kidney disease (CKD); economics; safety; Retacrit;
Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study
Keywords: Mortality; cardiovascular; safety; myocardial infarction; stroke; hemodialysis; darbepoetin alfa (DPO); epoetin alfa (EPO); recombinant erythropoietin; erythropoiesis-stimulating agent (ESA); renal replacement therapy (RRT);
A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial
Keywords: Anemia; chronic kidney disease (CKD); darbepoetin; drug sensitivity; epoetin; erythropoiesis-stimulating agent (ESA); ESA hyporesponsiveness; ESA resistance index (ERI); erythropoietin; pentoxifylline; hemoglobin; dialysis; randomized controlled trial;
Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis
Keywords: Erythropoietin; erythropoiesis-stimulating agent (ESA); epoetin; darbepoetin; anemia; chronic kidney disease (CKD); dose; mortality; cardiovascular morbidity; metaregression;
Anaemia in elderly patients with cancer: Focus on chemotherapy-induced anaemia
Keywords: Chemotherapy-induced anaemia (CIA); i.v. iron; Red blood cell (RBC) transfusion; Erythropoiesis-stimulating agent (ESA); Elderly
Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
Keywords: Erythropoiesis-stimulating agent (ESA); chronic kidney disease (CKD); hemoglobin variability; iron markers; ESA hyporesponsiveness; high-turnover bone disease; confounding by medical indication (CMI); repeated-measure model;